National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting, 58265-58266 [2018-25190]
Download as PDF
<![CDATA[
Federal Register / Vol. 83, No. 223 / Monday, November 19, 2018 / Notices
khammond on DSK30JT082PROD with NOTICES
Podcasting website (https://
videocast.nih.gov).
A portion of the National Cancer
Advisory Board meeting will be closed
to the public in accordance with the
provisions set forth in section
552b(c)(6), Title 5 U.S.C., as amended,
for the review, discussion, and
evaluation of individual intramural
programs and projects conducted by the
National Cancer Institute, including
consideration of personnel
qualifications and performance, and the
competence of individual investigators,
the disclosure of which would
constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Cancer
Advisory Board, Ad Hoc Subcommittee on
Global Cancer Research.
Open: December 3, 2018, 5:30 p.m. to 7:00
p.m.
Agenda: Discussion on Global Cancer
Research.
Place: Gaithersburg Marriott
Washingtonian Center, 9751 Washington
Boulevard, Gaithersburg, MD 20878.
Contact Person: Dr. Robert T. Croyle,
Acting Executive Secretary, NCAB Ad Hoc
Subcommittee on Global Cancer Research,
National Cancer Institute—Shady Grove,
National Institutes of Health, 9609 Medical
Center Drive, Room 4E420, Bethesda, MD
20892, (240) 276–6690, croyler@mail.nih.gov.
Name of Committee: NCI Board of
Scientific Advisors and National Cancer
Advisory Board.
Open: December 4, 2018, 8:45 a.m. to 4:15
p.m.
Agenda: Joint meeting of the NCI Board of
Scientific Advisors and National Cancer
Advisory Board—NCI Director’s report,
presentations, and review of concepts.
Closed: December 4, 2018, 4:15 p.m. to
5:15 p.m.
Agenda: Review of intramural program site
visit outcomes and the discussion of
confidential personnel issues.
Place: National Cancer Institute—Shady
Grove, 9609 Medical Center Drive, Room
TE406 & 408, Rockville, MD 20850.
Contact Person: Paulette S. Gray, Ph.D.,
Director, Division of Extramural Activities,
National Cancer Institute—Shady Grove,
National Institutes of Health, 9609 Medical
Center Drive, Room 7W444, Bethesda, MD
20892, 240–276–6340, grayp@mail.nih.gov.
Name of Committee: NCI Board of
Scientific Advisors and National Cancer
Advisory Board.
Open: December 5, 2018, 9:00 a.m. to 12:45
p.m.
Agenda: Joint meeting of the NCI Board of
Scientific Advisors and National Cancer
Advisory Board—Presentations and review of
concepts.
Place: National Cancer Institute—Shady
Grove, 9609 Medical Center Drive, Room
TE406 & 408, Rockville, MD 20850.
Contact Person: Paulette S. Gray, Ph.D.,
Director, Division of Extramural Activities,
National Cancer Institute—Shady Grove,
National Institutes of Health, 9609 Medical
VerDate Sep<11>2014
17:20 Nov 16, 2018
Jkt 247001
Center Drive, Room 7W444, Bethesda, MD
20892, 240–276–6340, grayp@mail.nih.gov.
Any interested person may file written
comments with the committee by forwarding
the statement to the Contact Person listed on
this notice. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
In the interest of security, NIH has
instituted stringent procedures for entrance
onto the NCI-Shady Grove campus. All
visitors will be asked to show one form of
identification (for example, a governmentissued photo ID, driver’s license, or passport)
and to state the purpose of their visit.
Information is also available on the
Institute’s/Center’s home page: NCAB: https://
deainfo.nci.nih.gov/advisory/ncab/ncab.htm,
BSA: https://deainfo.nci.nih.gov/advisory/
bsa/bsa.htm, where an agenda and any
additional information for the meeting will
be posted when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology
Research; 93.397, Cancer Centers Support;
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
HHS)
Dated: November 14, 2018.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2018–25193 Filed 11–16–18; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institutes of Health,
HHS.
ACTION:
Notice.
Frm 00044
Fmt 4703
Sickle Cell Anemia Treatment Through
RIOK3 Inhibition
Available for licensing and
commercial development are methods
for the treatment of beta-globinapathies
such as sickle cell disease and betathalassemia by inhibiting the expression
and/or activity of RIOK3 in erythroid
cells such as primary erythroid
progenitor cell or a CD34+ erythroid
cells. RIOK3 inhibitors contemplated
within the scope of the invention can be
antibodies, siRNAs, microRNAs,
antisense oligonucleotides or small
molecules like Midostaurin, Axitinib,
Bosutinib, or Ruxolitinib.
Potential Commercial Applications:
• Sickle cell disease
• beta thalassemia
Development Stage:
• Early stage
Inventors: Bjorg Gudmundsdottir,
Laxminath Tumburu, John Tisdale (all
of NHLBI)
Intellectual Property: HHS Reference
No. E–200–2018; U.S Provisional Patent
Application 62/756,497 filed November
6, 2018.
Licensing Contact: Michael
Shmilovich, Esq, CLP; 301–435–5019;
shmilovm@mail.nih.gov.
Dated: November 7, 2018.
Michael A. Shmilovich,
Senior Licensing and Patenting Manager,
National Heart, Lung, and Blood Institute,
Office of Technology Transfer and
Development.
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S. to achieve
expeditious commercialization of
results of federally-funded research and
development.
FOR FURTHER INFORMATION CONTACT:
Licensing information may be obtained
by emailing the indicated licensing
contact at the National Heart, Lung, and
Blood, Office of Technology Transfer
and Development Office of Technology
Transfer, 31 Center Drive, Room 4A29,
MSC2479, Bethesda, MD 20892–2479;
telephone: 301–402–5579. A signed
Confidential Disclosure Agreement may
be required to receive any unpublished
information.
SUMMARY:
PO 00000
SUPPLEMENTARY INFORMATION:
Technology description follows.
[FR Doc. 2018–25194 Filed 11–16–18; 8:45 am]
Government-Owned Inventions;
Availability for Licensing
AGENCY:
58265
Sfmt 4703
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of a
meeting of the Division of Intramural
Research Board of Scientific Counselors.
The meeting will be closed to the
public in accordance with the
provisions set forth in section
552b(c)(6), Title 5 U.S.C., as amended
for the review, discussion, and
evaluation of individual intramural
programs and projects conducted by the
NATIONAL INSTITUTE OF ALLERGY
AND INFECTIOUS DISEASES,
including consideration of personnel
E:\FR\FM\19NON1.SGM
19NON1
58266
Federal Register / Vol. 83, No. 223 / Monday, November 19, 2018 / Notices
qualifications and performance, and the
competence of individual investigators,
the disclosure of which would
constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Division of Intramural
Research Board of Scientific Counselors,
NIAID.
Date: December 10–12, 2018.
Time: 8:00 a.m. to 10:00 a.m.
Agenda: To review and evaluate personal
qualifications and performance, and
competence of individual investigators.
Place: National Institutes of Health,
Building 50, 50 Center Drive, Bethesda, MD
20892.
Contact Person: Steven M. Holland, MD,
Ph.D., Chief, Laboratory of Clinical Infectious
Diseases, National Institutes of Health/
NIAID, Hatfield Clinical Research Center,
Bethesda, MD 20892–1684, 301–402–7684,
sholland@mail.nih.gov.
In the interest of security, NIH has
instituted stringent procedures for entrance
onto the NIH campus. All visitor vehicles,
including taxicabs, hotel, and airport shuttles
will be inspected before being allowed on
campus. Visitors will be asked to show one
form of identification (for example, a
government-issued photo ID, driver’s license,
or passport) and to state the purpose of their
visit.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: November 14, 2018.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory
Committee Policy.
Optimized Variants of the Broadly
Neutralizing HIV–1 gp41 Antibody,
10E8
Description of Technology
Scientists at the National Institute of
Allergy and Infectious Diseases (NIAID)
recently discovered a human
neutralizing antibody, 10E8, that binds
to the GP41 protein of HIV–1 and
prevents infection by HIV–1. 10E8
potently neutralizes up to 98% of
genetically diverse HIV–1 strains.
By engineering the 10E8 antibody,
NIAID scientists have improved the
properties of 10E8 that affect
manufacturability, such as solubility,
while preserving its neutralizing
breadth and potency.
10E8 variants are useful for passive
protection from infection, as
therapeutics, and as a tool for vaccine
development.
This technology is available for
licensing for commercial development
in accordance with 35 U.S.C. 209 and 37
CFR part 404.
Potential Commercial Applications
Connors (NIAID), Amarendra Pegu
(NIAID), Lisa Kueltzo (NIAID), Tatyana
Gindin (Columbia University), and
Lawrence Shapiro (Columbia
University).
Publications: Kwon, Y.D. et al. (2016)
Optimization of the Solubility of HIV-1Neutralizing Antibody 10E8 through
Somatic Variation and Structure-Based
Design. J Virol. 90(13): 5899–914.
[PMID: 27053554]
Intellectual Property: HHS Reference
Number E–133–2015 includes Patent
Cooperation Treaty Application Number
PCT/US2016/060390 filed November 3,
2016; Canadian Patent Application
Number 3003878 filed May 1, 2018;
China Patent Application Number TBD
filed May 1, 2018; European Patent
Application Number 16801639.2 filed
June 1, 2018; India Patent Application
Number 20187016184 filed 30 April
2018; U.S. Patent Application Number
15/772,443 filed 30 April 2018; South
Africa Patent Application Number 2018/
02875 filed 2 May 2018; Australia
Patent Application Number 2016349392
filed 4 May 2018.
Related Intellectual Property: HHS
Reference Number E–253–2011.
Licensing Contact: Dr. Vince
Contreras, 240–669–2823;
vince.contreras@nih.gov.
Dated: November 7, 2018.
Suzanne M. Frisbie,
Deputy Director, Technology Transfer and
Intellectual Property Office, National Institute
of Allergy and Infectious Diseases.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
• Passive protection to prevent HIV
infection
• Passive protection to prevent
mother-to-infant HIV transmission
• Gene-based vectors for anti-gp41
antibody expression
• Therapeutics for elimination of HIV
infected cells that are actively
producing virus
National Institutes of Health
Competitive Advantages
National Institutes of Health
• Among the most potent and broadly
neutralizing human antibodies isolated
to date
• Broad reactivity and high affinity to
most HIV–1 strains
• Improved manufacturability
relative to the natural 10E8 antibody
National Human Genome Research
Institute; Notice of Closed Meeting
[FR Doc. 2018–25190 Filed 11–16–18; 8:45 am]
BILLING CODE 4140–01–P
Government-Owned Inventions;
Availability for Licensing
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The invention listed below is
owned by an agency of the U.S.
Government and is available for
licensing.
FOR FURTHER INFORMATION CONTACT: Dr.
Vince Contreras, 240–669–2823;
vince.contreras@nih.gov. Licensing
information and copies of the U.S.
patent application listed below may be
obtained by communicating with the
indicated licensing contact at the
Technology Transfer and Intellectual
Property Office, National Institute of
Allergy and Infectious Diseases, 5601
SUMMARY:
khammond on DSK30JT082PROD with NOTICES
Fishers Lane, Rockville, MD, 20852; tel.
301–496–2644. A signed Confidential
Disclosure Agreement will be required
to receive copies of unpublished patent
applications.
SUPPLEMENTARY INFORMATION:
Technology description follows.
VerDate Sep<11>2014
17:20 Nov 16, 2018
Jkt 247001
Development Stage
• In vivo data available (animal)
Inventors: Peter D. Kwong (NIAID),
Young Do Kwon (NIAID), Ivelin S.
Georgiev (NIAID), Gilad A. Ofek
(NIAID), Baoshan Zhang (NIAID), Krisha
McKee (NIAID), John Mascola (NIAID),
Gwo-Yu Chuang (NIAID), Sijy O’Dell
(NIAID), Robert Bailer (NIAID), Mark
Louder (NIAID), Mangaiarkarasi Asokan
(NIAID), Richard Schwartz (NIAID),
Jonathan Cooper (NIAID), Kevin Carlton
(NIAID), Michael Bender (NIAID), Mark
PO 00000
Frm 00045
Fmt 4703
Sfmt 4703
[FR Doc. 2018–25189 Filed 11–16–18; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of a
meeting of National Advisory Council
for Human Genome Research.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
E:\FR\FM\19NON1.SGM
19NON1
]]>Agencies
[Federal Register Volume 83, Number 223 (Monday, November 19, 2018)]
[Notices]
[Pages 58265-58266]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-25190]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and Infectious Diseases; Notice of
Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of a meeting of the Division of
Intramural Research Board of Scientific Counselors.
The meeting will be closed to the public in accordance with the
provisions set forth in section 552b(c)(6), Title 5 U.S.C., as amended
for the review, discussion, and evaluation of individual intramural
programs and projects conducted by the NATIONAL INSTITUTE OF ALLERGY
AND INFECTIOUS DISEASES, including consideration of personnel
[[Page 58266]]
qualifications and performance, and the competence of individual
investigators, the disclosure of which would constitute a clearly
unwarranted invasion of personal privacy.
Name of Committee: Division of Intramural Research Board of
Scientific Counselors, NIAID.
Date: December 10-12, 2018.
Time: 8:00 a.m. to 10:00 a.m.
Agenda: To review and evaluate personal qualifications and
performance, and competence of individual investigators.
Place: National Institutes of Health, Building 50, 50 Center
Drive, Bethesda, MD 20892.
Contact Person: Steven M. Holland, MD, Ph.D., Chief, Laboratory
of Clinical Infectious Diseases, National Institutes of Health/
NIAID, Hatfield Clinical Research Center, Bethesda, MD 20892-1684,
301-402-7684, [email protected].
In the interest of security, NIH has instituted stringent
procedures for entrance onto the NIH campus. All visitor vehicles,
including taxicabs, hotel, and airport shuttles will be inspected
before being allowed on campus. Visitors will be asked to show one
form of identification (for example, a government-issued photo ID,
driver's license, or passport) and to state the purpose of their
visit.
(Catalogue of Federal Domestic Assistance Program Nos. 93.855,
Allergy, Immunology, and Transplantation Research; 93.856,
Microbiology and Infectious Diseases Research, National Institutes
of Health, HHS)
Dated: November 14, 2018.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2018-25190 Filed 11-16-18; 8:45 am]
BILLING CODE 4140-01-P
